Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|April 30, 2024
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC DegraderLianchao Liu, Abhijit Parolia, Yihan Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapyYi Bao, Yuanyuan Qiao, Jae Eun Choi, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2023
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory responseYuanyuan Qiao, Jesse W Wotring, Yang Zheng, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancerCaleb Cheng, Jing Hu, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven MalignanciesTongchen He, Lanbo Xiao, Yuanyuan Qiao, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
PIKfyve controls dendritic cell function and tumor immunityJae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, et al.
Nature Communications|June 28, 2024
PIKfyve, expressed by CD11c-positive cells, controls tumor immunityJae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Nature Genetics|October 3, 2025
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Pageof 3